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Gregory L. Moneta, MD, Abstracts Section EditorThe ulcerated leg severity assessment score for prediction of venous leg
ulcer healing
Kulkarni SR, Gohel MS, Minor WJ, et al. Br J Surgery 2007;94:189-93.
Conclusion: The Ulcerated Leg Severity Assessment (ULSA) score
identifies patients with venous ulcers unlikely to respond to conventional
treatment.
Summary:Most, but not all, venous ulcers will heal with compression
therapy. The authors sought to develop an assessment score to potentially
identify patients whose ulcers would not heal with conventional compres-
sion therapy and, therefore, should perhaps be offered alternative therapy for
ulcer healing early in their course. Baseline factors affecting venous ulcer
healing were assessed in patients with venous ulcers seen between March
1999 and August 2001. All patients were initially treated with multilayer
compression therapy. Variables related to 24-week healing were identified,
and a Cox regression model was developed to identify risk factors that
predicted ulcer healing. From this model, a scoring system was developed
and subsequently prospectively validated between February 2004 andMarch
2005.
The baseline study included 229 patients with venous ulcers. Patient
age, ulcer chronicity, and venous refill time (VRT) of 20 seconds were
identified as risk factors for nonhealing. The authors used these risk factors
and hazard ratios from the Cox analysis and derived the following formula:
Ulcerated Leg Severity Assessment (ULSA) score  age  chronicity – 50
(when VRT is 20 seconds). Patients with an ULSA score 50 had higher
24-week ulcer-healing rates than those with scores50. This was in both the
baseline study (P  .001) and the follow-up prospective validation study
performed in 86 patients (P  .007).
Comment: Optimal therapy for venous ulceration continues to be
debated. The authors suggest that an elevated ULSA score may indicate
patients who early in the course of treatment may benefit from therapies
other than compression therapy. Their data, however, shows no benefit with
use of these “alternative” therapies. It only identifies individuals who will not
do well with compression therapy. It certainly cannot be assumed patients
who do not do well with compression therapy will be benefited by alternative
therapies. Alternative therapies may also not work well in patients with
elevated ULSA scores.
Homocystine-lowering therapy and risks for venous thromboembo-
lism: A randomized trial
Ray JG, Kearon C, Yi Q. The Heart Outcomes Prevention Evaluation 2
(HOPE-2) Investigators. Ann Intern Med 2007;146:761-7.
Conclusion: The risk of symptomatic venous thromboembolism
(VTE) is not decreased by lowering homocystine levels with folic acid and
vitamins B6 and B12.
Summary: Elevated homocystine levels are a risk factor for VTE. It is,
however, unknown whether decreasing homocystine levels with vitamin
therapy will lower the risk of VTE. The authors sought to determine whether
lowering homocystine levels will lower the risk of symptomatic VTE. This
was a secondary analysis of data obtained as part of the Heart Outcomes
Prevention Evaluation 2 (HOPE-2) trial. Data were derived from 145
centers in 13 countries. Included in the study were 5522 persons aged 55 or
older who had diabetes or known cardiovascular disease with at least one risk
factor for vascular disease. Patients were randomized to receive vitamin
therapy consisting of 2.5 mg of folic acid, 1 mg of vitamin B12, and 50 mg
of vitamin B6, or to receive placebo. Medications were administered for 5
years. End points included symptomatic deep venous thrombosis or pulmo-
nary embolism.
In patients treated with vitamin therapy, the mean homocystine level
decreased 2.2 mol/L. In the placebo group, mean homocystine levels
increased 0.80 mol/L. There were 88 instances VTE with a mean fol-
low-up of 5 years. VTE rate was the same in the vitamin therapy group and
the placebo group (0.35/100 person-years; hazard ratio, 1.01; 95% confi-
dence interval [CI], 0.66 to 1.53). The risk for deep venous thrombosis was
not reduced by vitamin therapy (hazard ratio, 1.04; 95% CI, 0.63 to 1.72),
nor was the risk of pulmonary embolism (hazard ratio, 1.14; 95%CI, 0.57 to
2.28) or unprovoked VTE (hazard ratio, 1.21; 95% CI, 0.66 to 2.23).
Comment: The HOPE-2 trial evaluated the effect of homocystine-
lowering therapy on major arterial vascular disease. This article represents a
secondary analysis of the HOPE 2 trial. The trial did not include patients
specifically at high risk for VTE. Elevated homocystine is a relatively minor
risk factor for VTE, and therefore, it is not surprising that the minor decrease
in homocystine levels associated with vitamin therapy in the HOPE 2
participants did not result in a detectable rate of decrease of VTE. The data
1080cannot be applied to patients at high risk for VTE or those with markedly
elevated levels of homocystine. Nevertheless, this is another of a number of
studies that indicate that although elevated homocystine may be a risk factor
or marker for venous or arterial disease, vitamin therapy to lower the
homocystine levels does not appear to clinically affect vascular events.
Dental and periodontal status and risk for progression of carotid
atherosclerosis: The Inflammation and Carotid Artery Risk for Athero-
sclerosis Study dental substudy
Schillinger T, Kluger W, Exner M, et al. Stroke 2006;37:2271-6.
Conclusion:Oral hygiene and tooth loss are associated with increased
levels of carotid stenosis and predict future progression of carotid artery
atherosclerosis.
Summary: There may be a link between periodontal and dental disease
and atherosclerosis. It is suggested that chronic inflammation triggered by
periodontitis plays a role in the etiology of atherosclerosis. In this study, the
authors studied a subset of patients from the Inflammation and Carotid
Artery Risk for Atherosclerosis study. This is a prospective study involving
serial ultrasound assessments of patients likely to have clinically relevant
atherosclerosis of the carotid artery. For the current study, 411 patients were
randomly selected from the 1268 participants in the Inflammation and
Carotid Artery Risk for Atherosclerosis study. Patients were evaluated for
dental and periodontal status and oral hygiene at study entrance using three
World Health Organization validated indices: DMFT (decayed, missing,
filled teeth), SLI (Silness-Lowe index), and CPITN (community periodon-
tal index for treatment needs), respectively. Carotid duplex ultrasound was
used tomeasure carotid stenosis at baseline and after a median of 7.5months
(range, 6 to 9 months).
DMFT (P  .01), SLI (P  .048), CPITN (P  .007), and edentu-
lousness (P  .007) all were associated with baseline levels of carotid
stenosis. During this study period, progression of carotid stenosis was noted
in 48 of 411 patients (11.7%). Adjusted odds ratios were 1.11 (95%
confidence interval [CI], 1.01 to 1.22, P .032) for DMFT, 1.77 (95% CI,
1.09 to 2.79) for SLI, and 1.51 (95% CI, 0.89 to 2.45, P  0.16) for
CPITN. DMFT and SLI predicted disease progression independent of
cardiovascular risk factors and baseline degree of stenosis. Edentulous pa-
tients also had a higher risk for disease progression compared with patients
with teeth (adjusted odds ratio, 2.10; 95% CI, 106 to 4.16; P  .033).
Comment: The role of dental and periodontal disease in atherosclero-
sis is controversial. There are many possible explanations for an observed
association between dental disease and atherosclerosis, and unmeasured
cofounders like socioeconomics status may modify observed associations. It
may be that dental disease merely serves as an added inflammatory compo-
nent to an already inflammatory vascular disease or that transient bacteriemia
associated with poor dental hygiene affects the development of atheroscle-
rotic plaques. Speculation with regard to the role of dental disease and the
etiology of atherosclerosis will continue. There are so many potential known
and unknown confounding variables that it is very unlikely this question will
ever be settled to anyone’s satisfaction.
Smoking, hypertension, alcohol consumption and risk of abdominal
aortic aneurysm in men
Wong DR, Willett WC, Rimm EB. Am J Epidemiol 2007;165:838-45.
Conclusion: Alcohol consumption correlates with the diagnosis of
abdominal aortic aneurysm (AAA).
Summary:Moderate alcohol consumption appears to have a protective
effect for ischemic heart disease. Little known, however, about the effects of
alcohol consumption and AAA. The authors analyzed prospective, biannu-
ally updated data from the Health Professionals Follow-up Study (HPFS).
This is a prospective cohort of 51,529 United States men who were aged 40
to 75 years at the inception of the study in 1986. The authors excluded from
this analysis individuals without complete dietary alcohol information in the
database, those with a history of ischemic cardiac disease, and those with
history of stroke or transient ischemic attack. Also excluded were nondrink-
ers who had never used alcohol or who had stopped using alcohol during the
previous 10 years. This left 39,352men for analysis. The authors determined
the association between alcohol consumption in grams per day and the
incident diagnosis of AAA. This was assessed at baseline and updated every 4
years. Data were controlled for previously reported cardiovascular risk
factors.There were 576,374 person-years of follow-up and 376 newly diag-
nosed AAAs. Adjusting for other risk factors for AAA (smoking, hyperten-
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associated with AAA diagnosis (P  .03 for trend). There was a maximum
hazard ratio of 1.21 (95% confidence interval [CI], 0.78 to 1.87) for30.0
g (2 standard drinks) of daily alcohol consumption. The association for
highest levels of alcohol intake was 1.65 (95% CI, 1.03 to 2.64).
Comment: This is the first report to document an association between
alcohol consumption and AAA. The data convincingly demonstrate higher
levels of alcohol consumption increase the risk of AAA, even in patients
without pre-existing cardiovascular disease. Moderate alcohol consumption
may have some benefit in lowering the risk of ischemic heart disease.
However, higher levels of alcohol confer no benefit and actually appear
harmful to the cardiovascular system.
A sustained mortality benefit from screening for abdominal aortic
aneurysm
Kim LG, Scott AP, Ashton, HA. and the Multicentre Aneurysm Screening
Study Group. Ann Intern Med 2007;146:699-706.
Conclusions: The early mortality benefit of screening ultrasonography
in reducing abdominal aortic aneurysm (AAA)-related death is maintained
over the long term. Cost effectiveness for screening improves over time.
Summary: The authors sought to estimate the benefits of ultrasound
screening for AAA in terms of all-cause mortality and cost-effectiveness.
They compared AAA mortality in a group of patients invited to undergo
ultrasound screening vs a group that was not. Mean follow-up was 7 years.
This was a randomized trial of AAA screening that was conducted in four
centers in the United Kingdom (UK) using a population-based sample of
67,770 men aged 65 to 74 years. Patients with an AAA detected during
screening were entered into a surveillance program and offered surgery when
the aneurysm fulfilled predefined criteria. Cost analysis was performed using
unit costs from large samples applied to individual data. Mortality data were
obtained from the UK national database.
The hazard ratio for AAA mortality in the group invited for screening
compared with those not invited for screening was 0.53 (95% confidence
interval [CI], 0.42 to 0.68). In patients with normal results on initial
ultrasonography, the rupture rate of AAA was 0.54 ruptures (95% CI, 0.25
to 1.02 ruptures) per 10,000 person-years. The observed hazard ratio for all
cause mortality in the screened vs nonscreened men was 0.96 (95% CI, 0.93
to 1.00). Cost effectiveness analysis was estimated at US $19,500 (95% CI,
$12,400 to $39,800) per life-year gained based on aneurysm-related mor-
tality and $76,000 (95% CI, $33,000 to infinity) per life-year gained based
on all cause death.
Comment: This is a late analysis of data from The Multicentre Aneu-
rysm Screening Study (MASS) analyzing the effect of AAA screening on
mortality in older men. It shows the short- and intermediate-term benefits of
AAA screening continue in the longer term. An interesting side bit of data is
that in patients whose initial aortic diameter is 3 cm, aneurysm-related
death in the next 7 years is extraordinarily unusual. Additional screening
after an initial ultrasound with a negative result is not warranted for at least
up to 7 years after an initial negative result on a screening study.
The impact of postoperative discontinuation or continuation of
chronic statin therapy on cardiac outcome after major vascular surgery
Le Manach Y, Godet G, Coriat P, et al. Anesth Analg 2007;104:1326-33.
Conclusions: Discontinuation of chronic statin therapy after major
vascular surgery increases the risk of myocardial infarction. Statin therapy
should be reinstituted on the first postoperative day after major vascular
surgery.
Summary: Accumulating evidence indicates statins reduce periopera-
tive cardiac events. It is unknown when patients who receive chronic statin
therapy should resume statins after a major vascular procedure. The authors
sought to compare cardiac outcomes in patients receiving chronic statin
therapy who resumed statin therapy immediately postoperatively vs those
where statin therapy was discontinued, at least temporarily, during the
perioperative period. This was a retrospective analysis of a prospectively
maintained database. Included were patients who underwent infrarenal
aortic reconstruction for aneurysm or occlusive disease using endovascular
or open techniques. Patients were studied from January 2001 to December
2004. Patients undergoing emergency procedures were excluded.
Blood was obtained for troponin I measurements when the patient
arrived to the postanesthesia care unit and on the first, second, and third
postoperative days. Patients not chronically treated with statins were con-
sidered controls and did not receive perioperative statin therapy. Patients
chronically treated with statins were divided into two groups. The first was
the discontinuation group. These were 491 patients from January 2001 to
December 2003 in which the authors’ institution did not have specific
guidelines regarding postoperative statin re-administration. The continua-
tion group consisted of 178 patients from January 2004 where guidelines
were in place to continue statins up to the evening before surgery, with
resumption on the first postoperative day using either nasogastric or oral
administration. Intracohort (propensity score) and extracohort (Lee score)risk adjustments were performed to determine the significance of differences
in elevated troponin levels in the continuation vs discontinuation groups. A
troponin I level99th percentile or0.2 ng/mL was considered indicative
of myocardial necrosis.
In the discontinuation group, median delay between surgery and
resumption of statin therapy was 4 days, and in the continuation group, it
was 1 day (P  .001). With propensity score matching for likelihood of
preoperative treatment, the odds ratio associated with chronic statin treat-
ment to predict myonecrosis for patients with vs without early postoperative
statin resumption (continuation vs discontinuation groups) was 0.38 and
2.1 (relative risk reduction, 5.4; 95% confidence interval, 1.2 to 25.3, P 
.001). The odds ratio for myocardial necrosis after adjustment for the Lee
score was 0.38 in the continuation group and 2.1 in the discontinuation
group (P  .001). Postoperative statin withdrawal was an independent
predictor of postoperative elevated troponin levels (odds ratio, 2.9; 95%
confidence interval, 1.6 to 5.5).
Comment: Although this was not a randomized trial and it used
historic controls, the data suggest that early resumption of statin therapy in
patients chronically receiving statin therapy will reduce the incidence of
myocardial infarction. Although there was no difference in perioperative
mortality in the continuation vs discontinuation groups, perioperative myo-
cardial infarction in itself is an end point worth reducing. It has been
associated with greater risk of long-term death and with increased duration
of hospitalization. More and more evidence now suggests a deleterious
cardiac effect of withdrawing statin therapy in the perioperative period.
Partial thrombosis of the false lumen in patients with acute type B
aortic dissection
Tsai TT, Evangelista A, Nienaber CA. The International Registry of Acute
Aortic Dissection. N Engl J Med 2007;357:349-59.
Conclusion: After hospital discharge, patients with acute type B aortic
dissection and partial thrombosis of the false lumen are at increased risk of
death compared with patients with complete patency of the false lumen.
Summary: The International Registry of Acute Aortic Dissection
(IRAAD) tracks patients with acute aortic dissection at 22 aortic centers in
11 countries. This is a registry, and treatment during hospitalization is not
standardized but is conducted at the discretion of each patient’s physician
and institution.
Patients with acute aortic type B dissection have low in-hospital mor-
tality but survival rates after discharge range from 92% at 1 year to 48 to 82%
at 5 years. It has been suggested that patients with complete thrombosis of
the false lumen have improved outcomes compared with patients who have
a patent false lumen, with the patent false lumen thought to place the patient
at increased risk of aortic expansion and death (Am J Card 2001;87:1378-
82). The authors sought to determine the influence on mortality of partial
thrombosis of the false lumen. They defined partial thrombosis of the false
lumen as both flow and thrombus present in the false lumen.
Between 1996 and 2003, 201 patients with type B aortic dissection
were enrolled in IRAAD and survived to discharge from the hospital. The
authors developedmortality curves according to the status of the false lumen
(complete thrombosis vs partial thrombosis vs patent). False lumen status
was determined during the initial hospitalization. They used Cox propor-
tional hazard analysis to identify independent predictors of death on follow-
up.
There were 114 patients (56.7%) who, during the index hospitaliza-
tion, had a patent false lumen. Sixty-eight patients (33.8%) had partial
thrombosis of the false lumen, and 19 (9.5%) had complete thrombosis of
the false lumen. At 3 years, the mortality rate for patients with a patent false
lumen was 13.7%. The mortality rate for patients with partial thrombosis of
the false lumen was 31.6%, and mortality for those with complete thrombo-
sis was 22.6%  22.6% (median follow-up, 2.8 years; P  .003, log-rank
test). Postdischarge mortality was independently predicted by partial throm-
bosis of the false lumen (relative risk, 2.69; 95% confidence interval [CI],
1.45 to 4.98; P .002), a history of atherosclerosis (relative risk, 1.87; 95%
CI, 1.01 to 3.47; P  .05), and a history of aortic aneurysm (relative risk,
2.05; 95% CI, 1.07 to 3.93; P  .03).
Comment: The authors postulate their findings may reflect that a
patent false lumen is perfused by a proximal entry tear and then decom-
pressed through re-entry tears distally. When thrombus partially occludes
the lumen, these distal re-entry tears may be occluded, impeding outflow
and leading to an increase in mean arterial and diastolic pressure that results
in increased wall tension in the false lumen and increases the risk of aneurysm
expansion, with increased risk of rupture and redissection.
Sustained benefit at two years of primary femoral-popliteal stenting
compared with balloon angioplasty with optional stenting
Schillinger M, Sabeti S, Dick P, et al. Circulation 2007;115:2745-9.
Conclusions: At 2 years, there is a sustained morphologic benefit for
treatment of superficial femoral artery (SFA) obstructions using self-expand-
ing nitinol stents inserted primarily vs balloon angioplasty with optional
